Targeted exome capture and sequencing identifies novel PRPF31 mutations in autosomal dominant retinitis pigmentosa in Chinese families

Liping Yang, Xiaobei Yin, Lemeng Wu, Ningning Chen, Huirong Zhang, Genlin Li, Zhizhong Ma

ABSTRACT
Objectives: To identify disease-causing mutations in two Chinese families with autosomal dominant retinitis pigmentosa (adRP).
Design: Prospective analysis.
Patients: Two Chinese adRP families underwent genetic diagnosis. A specific hereditary eye disease enrichment panel (HEDEP) based on targeted exome capture technology was used to collect the protein coding regions of targeted 371 hereditary eye disease genes; high throughput sequencing was done with the Illumina HiSeq 2000 platform. The identified variants were confirmed with Sanger sequencing.
Setting: All experiments were performed in a large laboratory specialising in genetic studies in the Department of Ophthalmology, Peking University Third Hospital.
Results: Two novel mutations, including one splice site mutation (Int10 c.1074-2 A>T; p.Y359SfsX29) and one insertion (c.824_825insA; p.Y275X) of PRPF31 were identified in the two families. The two mutations segregated with the disease phenotype in their respective families.
Conclusions: Our findings broaden the spectrum of PRPF31 mutations causing adRP and the phenotypic spectrum of the disease in Chinese patients. The HEDEP based on targeted exome capture technology is an efficient method for molecular diagnosis in adRP patients.

INTRODUCTION
Retinitis pigmentosa (RP) is an inherited retinal degeneration that affects approximately one in 3500 individuals, with an estimated total of 1.5 million patients worldwide. Typically patients affected by RP first suffer from night blindness, most often during adolescence. Rod and cone photoreceptor cells start to degenerate from the mid periphery to the far periphery and the centre of the retina, resulting in the so-called tunnel vision. Later in life, central vision is also lost, leading to legal or complete blindness. Clinical hallmarks of RP include bone spicule deposits, attenuated retinal blood vessels, optic disc pallor, visual field loss, and abnormal, diminished or non-recordable electroretinographic responses.

Strengths and limitations of this study
▪ The HEDEP based on targeted exome capture technology is an efficient method for molecular diagnosis in adRP patients.
▪ Both mutations result in premature termination codons before the last exon, thus insufficient functioning due to haploinsufficiency instead of aberrant function of the mutated proteins seems to be the most probably reason in these two families. However no experiment was done to prove it in this study.

LY, XY and LW contributed equally

Received 14 September 2013
Revised 24 September 2013
Accepted 14 October 2013
novel mutations unreported. It would be advantageous to screen for all the variants in the protein coding regions of targeted genes. One approach to achieve this is to develop a specific hereditary eye disease enrichment panel (HEDEP) based on exome capture technology to re-sequence simultaneously all the exons from targeted genes.

The aim of this study is to describe the development of a specific HEDEP and its application in molecular diagnosis of two Chinese families with adRP, and to characterise the phenotypic manifestation associated with the mutation.

MATERIALS AND METHODS

Study subjects and clinical evaluation

Two Chinese families of Han ethnicity with adRP were identified in the Anhui and Hubei provinces, respectively; there was no history of other ocular or systemic abnormalities in the families. The family adRP-19 has 16 affected individuals in four generations; 14 individuals (nine affected and five unaffected) participated in the study (figure 1A). The family adRP-61 has 18 affected individuals in three generations; 17 individuals (nine affected and eight unaffected) participated (figure 1B). Medical and ophthalmic histories were obtained, and ophthalmological examination was carried out. One hundred sporadic RP patients recruited in the Department of Ophthalmology, Peking University Third Hospital were used for RPPF31 gene mutation screening. One hundred healthy individuals from the Chinese Han ethnic population were recruited to serve as controls. All procedures used in this study conformed to the tenets of the Declaration of Helsinki. All experiments involving DNA and RNA of the patients and their relatives were approved by the Peking University Third Hospital Medical Ethics Committee. Informed consent was obtained from all participants.

Screening for mutations

Blood samples were collected and genomic DNA was extracted by standard protocols (D2492 Blood DNA Maxi Kit, Omega Bio-Tek, Norcross, Georgia, USA). A specific HEDEP based on targeted exome capture technology was used to collect the protein coding regions of targeted genes. This HEDEP was able to capture 371 hereditary eye disease genes, which cover 24 adRP associated genes (Best 1, CIQTFN5, CA4, CRX, FSCN2, GUCA1B, IMPDH1, KLHL7, NR2E3, NLR, PRPF3, PRPF31, PRPF6, PRPF8, PRPH2, RDH12, RHO, ROM1, RP1, RP9, RPE65, SEMA4A, SNRP200 and TOPORS). Genomic DNA (50 μg) from two patients (III3 and IV14), one carrier (III7) and one control (III18) of family adRP-19, and three patients (III13, III30 and IV2) and one control (II2) of family adRP-61 were used for targeted exome capture. The exon-enriched DNA libraries were then prepared for high throughput sequencing with the Illumina HiSeq 2000 platform. The obtained mean exome coverage was more than 98%, with variants accuracy at more than 99%. In these two families, we only analysed mutations that occurred in 24 adRP related genes. The shared changes in the affected individuals but not in the normal control were identified. The changes were filtered against exome data from ethnic Han Chinese Beijing available in the 1000 Genomes Project (http://www.1000genome.org), and against the Han Chinese Beijing SNPs in the dbSNP131. Sanger sequencing was then used to validate the identified potential disease-causing variants. Splice-site variants were analysed using the prediction program AUGUSTUS (http://bioinf.uni-greifswald.de/augustus/submission).

Mutation validation

The shared variants in the affected individuals but not in the normal control were then confirmed by direct PCR product sequencing using Bigdye terminator V3.1 cycle sequencing kits (Applied Biosystems, Foster City, California, USA) and analysed on an ABI 3130XL genetic analyzer. Sanger sequencing was used to determine whether the variant co-segregated with the disease phenotype in these two families. Primer pairs for individual exons were designed using the primer program (http://www.yeastgenome.org/cgi-bin/web-primer) (DNA reference number NG_009759). PCR primers, annealing temperatures, and amplimer-specific details are listed in table 1.

Isolation of total RNA and reverse transcription PCR analysis

Total RNA was extracted from peripheral whole blood samples by standard protocols (R6814 Blood RNA Kit, Omega). Reverse transcription (RT) was performed with oligonucleotide primers using Superscript II reverse transcriptase according to the manufacturer’s protocol (Invitrogen Corporation, Grand Island, New York, USA). Primers for RT-PCR were designed to amplify exons 7–12 of PRPF31 mRNA (mRNA reference number NM_015629). The forward primer is 5’-GCCAGATCATGGGTGTGG-3’, and the reverse primer is 5’-TGCAGCGTCTTGAGATCCT-3’. The RT-PCR products were further cloned into plasmids for sequence analysis.

RESULTS

Phenotype details

The clinical features of 14 members of family adRP-19 and 17 members of family adRP-61 who participated in this study are shown in table 2. All the tested affected individuals except III7 complained of night blindness and photophobia since childhood. Onset of the disease was noted range from 2 to 12 years of age. Fundus examination in the 38-year-old proband (IV14) of family adRP-19 showed bone spicule like pigmentation in the peripheral part of the retina, retinal arteriolar...
attenuation and retinal pigment epithelium (RPE) degeneration (figure 2A, B). Fundus examination in the 48-year-old proband (III9) of family adRP-61 showed bone spicule like pigmentation in the mid-periphery retina, bilateral attenuation of retinal vessels, RPE degeneration and pale optic disc (figure 2C, D). The 68-year-old asymptomatic carrier (III7) of family adRP-19 did not complain of night blindness, and fundus examination showed no RP changes in both eyes. Visual acuity in the majority of the patients declined quickly after 40 years of age.

Identification of mutations in PRPF31
We selected four individuals in each family for targeted exome capture. We generated an average of 0.77 Gb of sequence with 228× average coverage for each individual with paired 100 bp reads. The generated sequence covered an average of 99.2% of the targeted bases with the accuracy of a variant call more than 99%, which is sufficient to pass the thresholds for calling SNPs and short insertions or deletions (indels). We filtered all the detected variants and found the potential disease causing mutations. Then we compared the shared variants in affected individuals with the ethnic Han Chinese Beijing available in the 1000 Genomes Project (ftp://www.1000genome.org), and against the Han Chinese Beijing SNPs in the dbSNP131. This left one splice site variation (Int10 c.1074-2 A>T) in family adRP-19 and one insertion (c.824_825insA; p.Y275X) in family adRP-61, which was shared among affected individuals but not in the normal control in each family. Sanger sequencing validation and segregation analysis was carried out, which demonstrated that these two variants (figure 3) co-segregated with the disease phenotype in each family (figure 1), but was absent in 100 matched normal controls.

We further carried out direct PCR sequencing of the PRPF31 exons in an additional 100 unrelated sporadic RP patients. All of these patients showed typical RP fundus features, including bilateral attenuation of retinal vessels,
Table 2  Clinical data of the family members participating in the study

<table>
<thead>
<tr>
<th>Family ID</th>
<th>Sex</th>
<th>Age (y)</th>
<th>Disease status</th>
<th>Onset age (y)</th>
<th>R eye</th>
<th>L eye</th>
<th>Fundus features</th>
</tr>
</thead>
<tbody>
<tr>
<td>adRP-19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II:1</td>
<td>F</td>
<td>82</td>
<td>Yes</td>
<td>Childhood</td>
<td>LP</td>
<td>LP</td>
<td>Cataract, can’t see the fundus</td>
</tr>
<tr>
<td>II:3</td>
<td>F</td>
<td>80</td>
<td>Yes</td>
<td>8</td>
<td>LP</td>
<td>LP</td>
<td>Cataract, can’t see the fundus</td>
</tr>
<tr>
<td>III:2</td>
<td>F</td>
<td>58</td>
<td>Yes</td>
<td>3</td>
<td>LP</td>
<td>LP</td>
<td>Cataract, can’t see the fundus</td>
</tr>
<tr>
<td>III:3</td>
<td>M</td>
<td>54</td>
<td>Yes</td>
<td>3</td>
<td>0.1</td>
<td>0.1</td>
<td>Bilateral attenuation of retinal vessels, bone spicule pigments throughout the fundus, RPE degeneration, pale optic disc</td>
</tr>
<tr>
<td>III:6</td>
<td>M</td>
<td>46</td>
<td>No</td>
<td>–</td>
<td>1.5</td>
<td>1.5</td>
<td>No RP changes in both eyes</td>
</tr>
<tr>
<td>III:7</td>
<td>F</td>
<td>65</td>
<td>No</td>
<td>–</td>
<td>0.9</td>
<td>0.8</td>
<td>No RP changes in both eyes</td>
</tr>
<tr>
<td>III:18</td>
<td>M</td>
<td>68</td>
<td>No</td>
<td>–</td>
<td>1.2</td>
<td>1.2</td>
<td>No RP changes in both eyes</td>
</tr>
<tr>
<td>IV:3</td>
<td>F</td>
<td>29</td>
<td>Yes</td>
<td>Childhood</td>
<td>1.0</td>
<td>1.0</td>
<td>Bone spicule pigments in peripheral part of the fundus</td>
</tr>
<tr>
<td>IV:5</td>
<td>F</td>
<td>27</td>
<td>Yes</td>
<td>Childhood</td>
<td>1.0</td>
<td>1.0</td>
<td>Bone spicule pigments in peripheral part of the fundus</td>
</tr>
<tr>
<td>IV:14</td>
<td>M</td>
<td>38</td>
<td>Yes</td>
<td>3</td>
<td>0.3</td>
<td>0.5</td>
<td>Bilateral attenuation of retinal vessels, bone spicule pigments in peripheral part of the fundus, RPE degeneration</td>
</tr>
<tr>
<td>IV:15</td>
<td>F</td>
<td>34</td>
<td>No</td>
<td>–</td>
<td>1.5</td>
<td>1.5</td>
<td>No RP changes in both eyes</td>
</tr>
<tr>
<td>IV:17</td>
<td>F</td>
<td>37</td>
<td>No</td>
<td>–</td>
<td>1.5</td>
<td>1.2</td>
<td>No RP changes in both eyes</td>
</tr>
<tr>
<td>V:3</td>
<td>M</td>
<td>16</td>
<td>Yes</td>
<td>2</td>
<td>1.2</td>
<td>1.2</td>
<td>Bone spicule pigments in peripheral part of the fundus</td>
</tr>
<tr>
<td>V:6</td>
<td>M</td>
<td>3</td>
<td>Yes</td>
<td>2</td>
<td>1.2</td>
<td>1.2</td>
<td>Bone spicule pigments in peripheral part of the fundus</td>
</tr>
<tr>
<td>adRP-61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II:9</td>
<td>M</td>
<td>80</td>
<td>No</td>
<td>–</td>
<td>1.0</td>
<td>1.0</td>
<td>No RP changes in both eyes</td>
</tr>
<tr>
<td>III:1</td>
<td>F</td>
<td>63</td>
<td>Yes</td>
<td>12</td>
<td>0.4</td>
<td>0.5</td>
<td>Bone spicule pigments in peripheral part of the fundus</td>
</tr>
<tr>
<td>III:2</td>
<td>M</td>
<td>63</td>
<td>No</td>
<td>–</td>
<td>0.8</td>
<td>0.8</td>
<td>No RP changes in both eyes</td>
</tr>
<tr>
<td>III:3</td>
<td>M</td>
<td>61</td>
<td>No</td>
<td>–</td>
<td>1.0</td>
<td>1.0</td>
<td>No RP changes in both eyes</td>
</tr>
<tr>
<td>III:7</td>
<td>F</td>
<td>49</td>
<td>No</td>
<td>–</td>
<td>1.2</td>
<td>1.0</td>
<td>No RP changes in both eyes</td>
</tr>
<tr>
<td>III:9</td>
<td>F</td>
<td>48</td>
<td>Yes</td>
<td>Childhood</td>
<td>0.06</td>
<td>0.06</td>
<td>Bilateral attenuation of retinal vessels, bone spicule pigments throughout the fundus, RPE degeneration, pale optic disc</td>
</tr>
<tr>
<td>III:10</td>
<td>M</td>
<td>50</td>
<td>No</td>
<td>–</td>
<td>1.2</td>
<td>1.2</td>
<td>No RP changes in both eyes</td>
</tr>
<tr>
<td>III:12</td>
<td>M</td>
<td>40</td>
<td>Yes</td>
<td>Childhood</td>
<td>0.5</td>
<td>0.6</td>
<td>Bone spicule pigments in peripheral part of the fundus</td>
</tr>
<tr>
<td>III:13</td>
<td>M</td>
<td>38</td>
<td>Yes</td>
<td>Childhood</td>
<td>0.7</td>
<td>0.6</td>
<td>Bone spicule pigments in peripheral part of the fundus</td>
</tr>
<tr>
<td>III:14</td>
<td>M</td>
<td>45</td>
<td>No</td>
<td>–</td>
<td>1.0</td>
<td>1.0</td>
<td>No RP changes in both eyes</td>
</tr>
<tr>
<td>III:22</td>
<td>F</td>
<td>64</td>
<td>No</td>
<td>–</td>
<td>1.2</td>
<td>1.2</td>
<td>No RP changes in both eyes</td>
</tr>
<tr>
<td>III:25</td>
<td>M</td>
<td>50</td>
<td>Yes</td>
<td>Childhood</td>
<td>0.2</td>
<td>0.1</td>
<td>Bilateral attenuation of retinal vessels, bone spicule pigments throughout the fundus, RPE degeneration, pale optic disc</td>
</tr>
<tr>
<td>III:30</td>
<td>M</td>
<td>49</td>
<td>Yes</td>
<td>Childhood</td>
<td>0.1</td>
<td>0.06</td>
<td>Bilateral attenuation of retinal vessels, bone spicule pigments throughout the fundus, RPE degeneration, pale optic disc</td>
</tr>
<tr>
<td>IV:2</td>
<td>M</td>
<td>32</td>
<td>Yes</td>
<td>Childhood</td>
<td>0.7</td>
<td>0.6</td>
<td>Bone spicule pigments in peripheral part of the fundus</td>
</tr>
<tr>
<td>IV:5</td>
<td>F</td>
<td>35</td>
<td>Yes</td>
<td>Childhood</td>
<td>0.9</td>
<td>0.7</td>
<td>Bone spicule pigments in peripheral part of the fundus</td>
</tr>
<tr>
<td>IV:8</td>
<td>F</td>
<td>28</td>
<td>No</td>
<td>–</td>
<td>1.5</td>
<td>1.5</td>
<td>No RP changes in both eyes</td>
</tr>
<tr>
<td>IV:11</td>
<td>F</td>
<td>40</td>
<td>Yes</td>
<td>Childhood</td>
<td>0.5</td>
<td>0.6</td>
<td>Bone spicule pigments in peripheral part of the fundus</td>
</tr>
</tbody>
</table>

RP, retinitis pigmentosa; RPE, retinal pigment epithelium.
bone spicule pigments throughout the fundus, RPE degeneration and pale optic disc. No disease causing mutations were identified in these 100 sporadic patients.

Functional characterisation of the Int10 c.1074-2 A>T mutation using RT-PCR

To determine whether the Int10 c.1074-2 A>T splicing mutation in family adRP-19 has any effect on mRNA splicing, we performed RT-PCR for PRPF31 using total RNA samples isolated from peripheral blood samples from two patients (IV3 and V3), one unaffected family member (IV15) and two normal controls not related to the family. The RT-PCR products were further cloned into plasmids for sequence analysis. It yielded a 590 bp product from normal control samples as expected with normal splicing. One 590 bp fragment and another 517 bp product were amplified from the sample of affected individuals. Sequence analysis showed that the 517 bp product skipped exon11, resulting in frameshift — ie, p.Y359SfsX29 leading to premature termination with 28 new amino acids downstream. The sequence comparison details between wild type and mutated are listed in online supplementary figure S1.

DISCUSSION

In this study we reported the identification of two novel mutations—one splice site mutation (Int10 c.1074-2 A>T; p.Y359SfsX29) and one insertion (c.824_825insA; p.Y275X) of PRPF31 in two Chinese adRP families. The identified splice site mutation (Int10 c.1074-2 A>T; p.Y359SfsX29) in family adRP-19 segregated in all nine affected patients and one asymptomatic carrier, the mother of an affected patient who manifested the disease from childhood. The identified insertion mutation (c.824_825insA; p.Y275X) in family adRP-61 segregated in all the nine affected patients, including one woman who inherited the mutation from her 65-year-old asymptomatic father. This is consistent with incomplete penetrance of the PRPF31 mutation.

The human PRPF31 gene contains 14 exons and encodes a 61 kDa protein of 499 amino acids, the core component of the U4/U6•U5 tri-snRNP complex which constitutes a major building block of the pre-mRNA processing spliceosome.9 Although PRPF31 is ubiquitously expressed, patients with mutant PRPF31 alleles only show symptoms in the retina and not in other organs.10 At present, up to 50 mutations (including 15 splice defects, 10 missenses, 23 deletions and 2 insertions) in PRPF31 have been reported to be linked with adRP and sporadic RP cases.5 11 12 Splice defect have been reported in Int1,13 Int2,14 Int4,14 Int5,15 Int6,16 Int8,14 Int10,17 Int11 and Int13.10 18 Insertions have been reported in exon 7 and exon 8.19 All the above splice defect and insertion mutations resulted in frameshift, leading to premature termination. A previous study from Rio Frio et al20 demonstrated that most PRPF31 mutations bearing premature termination codons (PTCs)
before the last exon behave as null allele, resulting in haploinsufficiency as their corresponding mRNA is degraded by nonsense-mediated mRNA decay (NMD). However, if the PTC produced by the mutation occurs in the last exon of a given gene, the mutant mRNA is insensitive to NMD and is thought to be translated into a truncated protein.21 The splice site mutation (Int10 c.1074-2 A>T) in the present study caused the skipping of exon 11, resulting in frameshift, leading to premature termination with 28 new amino acids downstream (ie, p.Y359SfsX29). The insertion mutation (c.824_825insA) in the present study happened in exon 8, resulting in the following amino acid changing from Thr to stop codon (p.Y275X). Since both mutations result in PTC before the last exon, insufficient functioning due to haploinsufficiency instead of aberrant function of the mutated proteins seems to be the most probable cause in these two families.

Several studies have been reported on the use of genotyping microarray for genetic diagnosis of retinal disease, such as Stargardt disease,22 Leber congenital amaurosis,23 Usher syndrome,24 autosomal recessive RP25 and adRP.7 Different from arrayed primer extension technology used in most of previous microarray studies, the HEDEP in this study was based on target exon capture technology.

Figure 3  Sequencing results of the PRPF31 mutations in the two families. (A) Family autosomal dominant retinitis pigmentosa (adRP)-19 carried the mutation Int10 c.1074-2 A>T; p.Y359SfsX29. (B) Family adRP-61 carried the mutation c.824_825insA; p.Y275X.
hereditary eye disease genes, which cover 53 RP associated genes, 7 Stargardt associated genes, 19 Leber congenital amaurosis associated genes, 11 Usher syndrome associated genes, 33 cone and rod dystrophy associated genes, 13 choroideremia atrophy associated genes, 35 microphthalmia associated genes, 46 congenital cataract associated genes, 4 glaucoma associated genes, 6 familial exudative vitreoretinopathy associated genes and 35 RP related syndrome associated genes. It is applicable to genetic study of broader inherited eye disease. Sanger sequencing in this study confirmed the mutation previously detected with the HEDEP, which proved the sensitivity and specificity of the HEDEP for application in molecular diagnosis of inherited eye diseases.

We presented a successful genetic diagnosis with a specific HEDEP, and identified two novel mutations—one splice site mutation (Int10 c.1074-2 A>T; p.Y359SfsX29) and one insertion (c.824_825insA; p.Y275X) of PRPF31—in two Chinese adRP families with incomplete penetrance. Both mutations resulted in PTC before the last exon, thus insufficient functioning due to haploinsufficiency was the most probable cause in these two families. Our findings broaden the spectrum of PRPF31 mutations causing adRP and the phenotypic spectrum of the disease in Chinese patients, which will be helpful for genetic consultation and genetic diagnosis in the future.

Author affiliations
1 Department of Ophthalmology, Peking University Third Hospital, Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing, P. R. China
2 Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, P. R. China

Acknowledgements The authors are grateful to all family members for their participation in this study.

Contributors Conceived and designed the experiment: LY, HZ, GL and ZM. Performed the experiments: LY, XY, LW and NC. Analysed the data: LY, LW and NC. Wrote the paper: LY and ZM.

Funding This study was supported by the National Natural Science Foundation of China (Grant 81170877).

Competing interests None.

Patient consent Obtained.

Ethics approval This study was conducted with the approval of Peking University Third Hospital Medical Ethics Committee (No. 2012093).

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement The original sequencing results are available on request.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

REFERENCES